President Donald Trump’s nominee to lead the Centers for Disease Control and Prevention (CDC), Dr. Erica Schwartz, has moved closer to confirmation after Senator Bill Cassidy, chairman of the Senate Health, Education, Labor and Pensions Committee, indicated he will support her nomination. This development comes amid concerns about the agency’s management and policy direction under Health Secretary Robert F. Kennedy Jr., whose controversial stance on vaccines has sparked debate.
Schwartz, a former deputy surgeon general and longtime Coast Guard health official, was nominated in April to restore stability to the CDC following a series of high-profile leadership changes. The agency has effectively lacked permanent leadership for much of Trump’s second term, with the previous director, Susan Monarez, dismissed within a month after disputes with Kennedy over vaccine policies. Kennedy has been widely criticized for promoting vaccine skepticism and for rolling back established vaccination programs.
During her confirmation hearing, Schwartz faced intense questioning from Cassidy and other senators regarding her ability to maintain scientific integrity and independence within the CDC. Cassidy, who is also a medical doctor, pressed Schwartz on whether she would stand up to Kennedy, particularly concerning vaccine policies that link vaccines to autism—a claim that is not supported by scientific evidence but was reportedly tolerated or advanced by Kennedy’s office. Schwartz declined to commit explicitly to opposing Kennedy’s directives, leading to frustration among some senators.
Despite initial reservations and a delayed committee vote attributed to attendance issues, Cassidy later expressed confidence in Schwartz’s qualifications after consulting further with her and reviewing the hearing transcript. He suggested that Schwartz would uphold the agency’s mission and resist efforts to undermine vaccine science. If the Senate committee approves her nomination, the full Senate will vote on her confirmation.
The narrow Republican majority in the committee means that a final confirmation vote could hinge on Cassidy’s support, as Senate Democrats, led by ranking member Bernie Sanders, have voiced opposition to Schwartz’s nomination. Critics argue that recent leadership turmoil and the influence of Kennedy and his allies have weakened the CDC’s ability to respond to public health challenges, such as the recent resurgence of measles, outbreaks of cyclospora, hantavirus cases, and concerns about other infectious diseases like Ebola and whooping cough.
Supporters of Schwartz contend that she can provide the firm scientific leadership necessary to rebuild trust and restore the CDC’s role as an independent public health authority. Opponents highlight her reluctance to directly confront Kennedy’s policies during hearings and question whether she can effectively reverse recent program rollbacks.
As the confirmation process continues, public health experts emphasize the importance of stable and science-driven leadership at the CDC, especially given the agency’s central role in managing emerging health threats and vaccine programs in the United States.